@article{fc3a878a955c45d986b225747bdab2ac,
title = "Standardized reporting criteria for studies evaluating suspected acute heart failure syndromes in the emergency department",
abstract = "Heart failure requiring urgent therapy represents a burgeoning health care burden. Although acute heart failure syndromes are commonly defined as a change in chronic heart failure signs and symptoms requiring urgent therapy, the presentation, development, and response to treatment is highly dependent on individual patient characteristics. This heterogeneity has led to challenges in interpreting widely differing study methods, including eligibility requirements and outcome measures. To improve interpretation of results and translate such information to better patient care, it is essential to present an accurate description of the patient population and study design. Based on existing recommendations and expert consensus, the authors present standardized reporting criteria to improve interpretability of research in this challenging cohort.",
keywords = "acute heart failure, emergency department, reporting criteria, study design",
author = "Storrow, {Alan B.} and Lindsell, {Christopher J.} and Collins, {Sean P.} and Diercks, {Deborah B.} and Filippatos, {Gerasimos S.} and Hiestand, {Brian C.} and Hollander, {Judd E.} and Kirk, {J. Douglas} and Levy, {Phillip D.} and Miller, {Chadwick D.} and Naftilan, {Allen J.} and Nowak, {Richard M.} and Pang, {Peter S.} and Peacock, {W. Frank} and Mihai Gheorghiade and Cleland, {John G F}",
note = "Funding Information: Dr. Nowak has research support relationships with Brahms and Nanosphere. Over the past 3 years, Dr. Miller was a speaker at a CME event supported by an educational grant from Sanofi Aventis ; has had consulting relationships with The Medicines Company and Breathquant Medical LLC; and has cardiovascular research support relationships with Biosite Inc., Johnson & Johnson/Scios Inc., POL Biopharma, GlaxoSmithKline, Siemens, BreathQuant Medical LLC, Heartscape Technologies Inc., and Schering-Plough. Dr. Hiestand has received research funding from Medtronic Inc., Biosite Inc., Inovise Medical Inc., Heartscape International, Nanosphere Inc., Mitsubishi Chemical Medience, and The Medicines Company; and has a medical writing consulting relationship with newMentor Inc. Dr. Collins has previous or current grant/research support relationships with Biosignetics , Inovise Medical Inc. , Abbott Point-of-Care , NIH/NHLBI , Corthera , and Brahms ; previous or current consulting relationships with Abbott Point-of-Care, POL BioPharma, Astellas, Otsuka Pharmaceuticals, and Bayer; and previous or current scientific advisory board relationships with Astellas, The Medicines Company, and Corthera. Dr. Levy has consulting relationships with The Medicines Company (Data Safety Monitoring Board), Corthera Inc., Bayer Schering Pharma AG, and EKR Therapeutics; has or had grant/research support relationships with the Robert Wood Johnson Foundation Physician Faculty Scholars Program , the National Institutes of Health Loan Repayment Program , The Cleveland Clinic Foundation , Nile Therapeutics , Astellas Pharma Inc. , Corthera Inc. , Solvay Pharmaceuticals Inc. , Bayer Schering Pharma AG , and Inovise Medical ; and has a Speakers' Bureau relationship with the Society of Chest Pain Centers. Dr. Peacock has ownership interest in Vital Sensors; has research/grant relationships with Abbott , BAS , Biosite , Brahms , Inverness , Nanosphere , EKR , and The Medicines Company ; has Scientific Advisory Board relationships with Abbott, Beckman-Coulter, Biosite, Inverness, and The Medicines Company; and has Speakers' Bureau relationships with Abbott and Biosite. Within the past 5 years, Dr. Pang is or has been a consultant for Astellas, Bayer, EKR Therapeutics, Johnson & Johnson, The Medicines Company, Otsuka, Palatin Technologies, PDL BioPharma, Pericor Therapeutics, SigmaTau, and Solvay Pharmaceuticals; has or had honoraria relationships with Biogenldec, Corthera, Ikaria, and Nile Therapeutics; and has or had research support relationships with Abbott, Merck, and PDL BioPharma. Dr. Cleland has investigator and advisory group relationships with Merck Sharpe and Dohme, Corthera/Novartis, and Actelion for which he has received research funding support and personal payment. Dr. Gheorghiade has consulting relationships with Abbott Labs, Astellas, AstraZeneca, Bayer Schering Pharma AG, Corthera Inc., Cytokinetics Inc., DebioPharm S.A., Errekappa Terapeutici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi Aventis, Sigma Tau, and Solvay Pharmaceuticals; and receives financial support from Bayer Schering Pharma AG, DebioPharm S.A., Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals, DebioPharm S.A., and Pericor Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",
year = "2012",
month = aug,
day = "28",
doi = "10.1016/j.jacc.2012.03.072",
language = "English (US)",
volume = "60",
pages = "822--832",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "9",
}